Course Description Form /Stage 5

| ✓ Course Name: | | | | | | |
|---|--|--|--|--|--|--|
| Dosage form des | Dosage form design | | | | | |
| ✓ Course Code: | | | | | | |
| 569 PDf | | | | | | |
| ✓ Semester / Year: | | | | | | |
| 2 nd 2023–20 | 024 | | | | | |
| ✓ Description Preparation Date: | | | | | | |
| 2024 | | | | | | |
| ✓ Available Attendance Forms: | | | | | | |
| yes | | | | | | |
| ✓ Number of Credit Hours (Total) / Number | of Units (Total) | | | | | |
| 2 Unit | | | | | | |
| ✓ Course administrator's name (mention | | | | | | |
| Name: Prof. Dr. Shaimaa Nazar Abdall | , | | | | | |
| Email: Shaimaa.Abd@copharm.uobagl | | | | | | |
| Linan. Shamaa.Abu@copharm.dobaghdad.edd.iq | | | | | | |
| | | | | | | |
| Assist. Prof. Dr. Lubna Abdalka | rim Sabri | | | | | |
| Assist. Prof. Dr. Lubna Abdalka Lobna.sabri@copharm.uobagh | | | | | | |
| Lobna.sabri@copharm.uobagh | | | | | | |
| | | | | | | |
| Lobna.sabri@copharm.uobagh | | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | dad.edu.iq | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing by the federal Food and Drug Administration. - Study the historical development of drugs and pharmacy, | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing by the federal Food and Drug Administration. - Study the historical development of drugs and pharmacy, | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing by the federal Food and Drug Administration. - Study the historical development of drugs and pharmacy, role of the pharmacist in contemporary practice, standards of | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing by the federal Food and Drug Administration. - Study the historical development of drugs and pharmacy, role of the pharmacist in contemporary practice, standards of United States Pharmacopeia–National Formulary, | | | | | |
| Lobna.sabri@copharm.uobaghe ✓ Course Objectives | The student will be able to: - understanding the regulatory process by which manufactured pharmaceuticals are approved for marketing by the federal Food and Drug Administration. - Study the historical development of drugs and pharmacy, role of the pharmacist in contemporary practice, standards of United States Pharmacopeia—National Formulary, - Compare and contrast an Investigational New Drug (IND) | | | | | |

- Differentiate between the various methods of drug discovery
- Delineate the circumstances whereby an old drug could be classified as "new"
- Define pharmacology, drug metabolism, and toxicology
- List common terms used in the Current Good
 Manufacturing Practice (cGMP) for finished
 pharmaceuticals
- Outline Code of Federal Regulation (CFR) such as the organization and personnel required, the intent and importance of written procedures within the various components of cGMP
- Describe the various types of tamper-evident packaging,
 and provide a product example of each type
- Differentiate between pharmaceutical manufacturing and extemporaneous compounding
- Compare and contrast the advantages/disadvantages of various drug dosage forms
- Describe the information needed in preformulation studies to characterize a drug substance for possible inclusion into a dosage form
- Describe the mechanisms of drug degradation and provide examples of each
- Describe the purpose and general protocol for accelerated stability studies
- Categorize various pharmaceutical ingredients and excipients
- Differentiate between different routes for active drug transport
- Discuss key data points in a blood plasma concentration time curve following

the oral administration of a drug

 Differentiate between the terms biopharmaceutics, bioavailability, and bioequivalence

- Discuss the importance of a drug's dissolution rate
 following the oral administration of a solid dosage form
- Describe the sequence of events and the processes that occur to a drug during its course of bodily transit, from the time of its oral administration and absorption through its excretion
- Perform various basic pharmacokinetic calculations

✓ Teaching and Learning Strategies

Strategy

Lectures and Presentation, Interactive discussions related photos and videos, brainstorm, and Inverted classrooms with learning strategies:

- 1. Tuning in ...can be used to determine students' current knowledge and skills.
- 2. Finding out ... encourage investigation and independent learning.
- 3- Sorting out ... encourage the analysis.
- 4- Developing values ... allow students to identify,
- 5- Speaking out ... provide opportunities for students to develop speaking.
- 6-Reflecting ... allow students to identify, discuss and consider the changes in their understandings.

✓ Course Structure

✓ Course Evaluation

Distributing the score out of 100 according to the tasks assigned to the student such as daily preparation, daily oral, monthly, or written exams, reports etc

✓ Learning and Teaching Resources

| Required textbooks (curricular books, if any) | Ansel's Pharmaceutical Dosage Forms and Drug Delivery |
|---|--|
| , | Systems |
| | by Loyd Allen 11 th ed. 2017 |
| Main references (sources) | Ansel's Pharmaceutical Dosage Forms and Drug Delivery |
| , | Systems |
| | by Loyd Allen 11 th ed. 2017 |
| Recommended books and references | Aulton's pharmaceutics: The design and manufacture of |
| (scientific journals, reports) | medicines. By Aulton M E and Taylor K G. 5 th edition. |
| | 2018 |
| Electronic References, Websites | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfr rch.cfm?fr=155.194 |

| Week | hours | Required Learning Outcomes | Unit or | Learning | Evaluation |
|-----------|---------------|---|------------------------|--|--|
| | | | subject name | method | method |
| 1. | 2 | -Introduction | Section 1 Chapter 1 | Presentation of lecture Interactive discussions | Discussion |
| 2. | 2 | Introduction to drugs and pharmacy; pharmaceutical consideration: the need for the dosage form. | Section 1 Chapter 1 | Presentation of lecture Interactive discussions | Discussion Daily exam |
| 3. | 2 | New Drug Development and Approval Process | Section 1 Chapter 2 | Presentation of lecture Interactive discussions | Discussion Daily exam |
| 4. | 2 | Methods of drug discovery, lead compound and goal drug | Section 1 Chapter 2 | Presentation of lecture Interactive discussions | Discussion Daily exam |
| 5. | 2 | Prodrugs | Section 1 Chapter 2 | Presentation of lecture Interactive discussions | Discussion Daily exam |
| 6. | 2 | Pharmacology, and Toxicology | Section 1 Chapter 2 | Presentation of lecture Interactive discussions | Discussion Daily exam |
| 7. | 2 | Acute or Short-Term Toxicity Studies | Section 1 Chapter 2 | Presentation of lecture Interactive discussions | Discussion Questions and answers Quiz |
| 8. | 2 | Carcinogenicity Studies, Reproduction Studies, Genotoxicity or Mutagenicity Studies | Section 1 Chapter 2 | Presentation of lecture and Related Photos and Videos | Discussion Quiz |
| 9. | 2 | Current Good Manufacturing Practices | Section 1 Chapter 3 | Presentation of lecture Interactive discussions | Discussion Questions and answer Brainstorming Quiz |
| 10. ✓ Coi | 2 irse Nar | Good Compounding Practices | Section 1 Chapter 3 | Presentation of lecture Interactive discussions | Discussion Questions and answer Brainstorming Quiz |

| 11. | 2 | | Section 1 | Presentation of | Discussion |
|-----|---|------------------------------------|-----------|-----------------|---------------|
| | | | Chapter 3 | lecture | Questions and |
| | | Packing, Labeling and Storage of | | Interactive | answer |
| | | Pharmaceutics | | discussions | Brainstorming |
| | | | | | Quiz |
| 12. | 2 | | Section 2 | Presentation of | Discussion |
| | | Dosage Form Design: | Chapter 4 | lecture | Quiz |
| | | Pharmaceutical and Formulation | | Interactive | Question and |
| | | Considerations | | discussions | answer |
| | | and Preformulation study | | Related photos | |
| | | | | and videos | |
| 13. | 2 | | Section 2 | Presentation of | Discussion |
| | | | Chapter 4 | lecture | Quiz |
| | | Drug Stability: Mechanisms of | | Interactive | Question and |
| | | degradation | | discussions | answer |
| | | | | Related photos | |
| | | | | and videos | |
| 14. | 2 | Drug excipients: Flavoring | Section 2 | Interactive | Questions and |
| | | Pharmaceuticals | Chapter 4 | discussions | answer |
| | | Sweetening Colorants and | | | Brainstorming |
| | | preservative | | | |
| 15. | 2 | Biopharmaceutical and | Section 2 | Interactive | Questions and |
| | | pharmacokinetic considerations: | Chapter 5 | discussions | answer |
| | | Dissolution and drug absorption | | | Brainstorming |
| 16. | 2 | Bioavailability and bioequivalence | Section 2 | Interactive | Questions and |
| | | Routes of administration | Chapter 5 | discussions | answer |
| | | Pharmacokinetic principles | | | Brainstorming |
| | | | | | |
| 17. | 2 | Review | | | |

Applied Therapeutics I

✓ Course Code:

559 CpAt1

✓ Semester / Year:

First semester/ Fifth

✓ Description Preparation Date:

02/2024

✓ Available Attendance Forms:

On campus

✓ Number of Credit Hours (Total) / Number of Units (Total)

3 Hours /3 Units

✓ Course administrator's name (mention all, if/ more than one name)

Name: Dr. Samer Imad Mohammed

Email: samer.jameel@copharm.uobaghdad.edu.iq

Name: **Dr. Basma Zuheir Muhammed Naji** Email: **basma.naji@copharm.uobaghdad.edu.iq** Name: Dr. Fadia Thamir Ahmed

Email: fadia.ahmed@copharm.uobaghdad.edu.iq

✓ Course Objectives

Course Objectives

- The course provides students with the basic knowledge about pathophysiology, symptoms and aims of treatment.
- In addition to the basic knowledge on the drug's use, kinetics, drug interactions, dose calculations, side effects, treatment algorithms and patient awareness are provided.

✓ Teaching and Learning Strategies

Strategy

Lectures Seminars

Simple quizzes

Brainstorming questions

✓ Course Structure

| Week | Hour | Required Learning Outcomes | Unit or subject | Learning | Evaluatio |
|------|------|---|---------------------|--------------|-----------|
| | s | | name | method | n method |
| 1 | 2 | 1. Differentiate between | Interpretation of | Lectures. | Simple |
| | | Sensitivity and Specificity of | clinical laboratory | Discussions. | quizzes. |
| | | lab tests. | data | | |
| | | 2. Identify reference ranges of | | | |
| | | lab tests. | | | |
| | | 3. Identify normal and | | | |
| | | abnormal liver function | | | |
| | | tests. | | | |
| | | 4. Identify normal and | | | |
| | | abnormal renal function | | | |
| | | tests. | | | |
| | | 5. Interpretation of complete blood count test results. | | | |
| | | 6. Interpretation of urinalysis | | | |
| | | main findings. | | | |
| | | 7. Interpretation of | | | |
| | | hematological lab | | | |
| | | investigations | | | |
| 2 | 2 | Identify the common types | Dyslipidemia. | Lectures. | Simple |
| | | of lipid disorders. | J 1 | Simple | quizzes. |
| | | 2. Identify the statin-benefit | | discussions. | 1 |
| | | groups and intensity of | | | |
| | | statin therapy. | | | |
| | | 3. Recommend appropriate | | | |
| | | therapeutic lifestyle | | | |
| | | changes (TLC) and | | | |

| | 1 | T , | | | |
|---|---|--|---------|--------------|----------|
| | | pharmacotherapy | | | |
| | | interventions for | | | |
| | | dyslipidemia. | | | |
| | | 4. Determine a patient's | | | |
| | | atherosclerotic | | | |
| | | cardiovascular disease risk | | | |
| | | and corresponding | | | |
| | | | | | |
| | | treatment goals. | | | |
| | | 5. Identify patients who are | | | |
| | | indicated for non-statin | | | |
| | | therapy. | | | |
| | | 6. Describe components of a | | | |
| | | monitoring plan to assess | | | |
| | | effectiveness and adverse | | | |
| | | effects of | | | |
| | | pharmacotherapy for | | | |
| | | dyslipidemias. | | | |
| | | | | | |
| | | 7. Educate patients about the | | | |
| | | disease state, appropriate | | | |
| | | TLC, and drug therapy | | | |
| | | required for effective | | | |
| | | treatment. | | | |
| 3 | 1 | 1. Differentiate types of | Stroke. | Lectures. | Simple |
| | | cerebrovascular disease | | Simple | quizzes. |
| | | including transient ischemic | | discussions. | - |
| | | attack (TIA), ischemic | | | |
| | | stroke (cerebral infarction), | | | |
| | | and hemorrhagic stroke. | | | |
| | | _ | | | |
| | | 2. Identify modifiable and | | | |
| | | nonmodifiable risk factors | | | |
| | | associated with ischemic | | | |
| | | stroke and hemorrhagic | | | |
| | | stroke. | | | |
| | | 3. Explain the pathophysiology | | | |
| | | of ischemic stroke and | | | |
| | | hemorrhagic stroke. | | | |
| | | 4. Describe the clinical | | | |
| | | presentation of TIA, | | | |
| | | ischemic stroke, and | | | |
| | | hemorrhagic stroke. | | | |
| | | 5. Formulate strategies for | | | |
| | | 9 | | | |
| | | primary prevention of acute | | | |
| |] | ischemic stroke. | | | |
| | | | | | |
| | | 6. Evaluate treatment options for acute ischemic stroke. | | | |

| | | Determine whether fibrinolytic therapy is indicated in a patient with acute ischemic stroke. Evaluate the role of endovascular therapy in a patient with acute ischemic stroke. Formulate strategies for secondary prevention of acute ischemic stroke. | | | |
|---|---|---|--|-------------------------------|-----------------|
| | | 10. Evaluate treatment options for acute hemorrhagic stroke. | | | |
| 4 | 1 | Assess a patient's kidney function based on clinical presentation, laboratory results, and urinary indices. Identify pharmacotherapeutic outcomes and endpoints of therapy in patients with acute kidney injury (AKI). Apply knowledge of the pathophysiology of AKI to develop a treatment plan. Develop strategies to minimize the occurrence of drug-induced AKI. Monitor and evaluate the safety and effectiveness of the treatment plan. | Acute kidney injury | Lectures. Simple discussions. | Simple quizzes. |
| 5 | 2 | List the risk factors that increase susceptibility for chronic kidney disease (CKD). Explain the mechanisms associated with progression of CKD. Outline the desired outcomes for treatment of CKD. Develop a therapeutic approach to slow progression of CKD including lifestyle | Chronic and end- stage kidney disease. | Lectures. Simple discussions. | Simple quizzes. |

| | | modifications and pharmacologic therapies. 5. Identify specific consequences associated with CKD. 6. Design an appropriate therapeutic approach for specific consequences associated with CKD. | | | |
|---|---|---|---------------------------------------|-------------------------------|-----------------|
| 6 | 1 | Identify indications for dialysis. List advantages and disadvantages of hemodialysis and peritoneal dialysis. Describe the principles and procedures of hemodialysis and peritoneal dialysis. Identify complications of hemodialysis and peritoneal dialysis and peritoneal dialysis and their management. | Hemodialysis and peritoneal dialysis. | Lectures. Simple discussions. | Simple quizzes. |
| 7 | 1 | Definition of pharmacovigilance. Recognize who should report the pharmacovigilance reports. Describe the importance of pharmacovigilance. Historical events reported ADRs. Describe Causality Assessment. Identify terms used in pharmacovigilance. Identify the importance of pharmacovigilance. | Pharmacovigilanc e. | Lectures. Simple discussions. | Simple quizzes. |
| 8 | 2 | Explain the pathophysiology of cirrhosis and portal hypertension. Identify signs and symptoms of cirrhosis. Identify laboratory abnormalities that result from liver disease and describe the associated pathophysiology. | Cirrhosis and portal hypertension. | Lectures. Simple discussions. | Simple quizzes. |

| | | 1 | D 1 1 | I | | |
|----|---|---|--|-----------------------------|-------------------------------|-----------------|
| | | 4. | Describe the consequences | | | |
| | | | associated with decreased | | | |
| | | | hepatic function. | | | |
| | | 5. | Identify treatment goals for a | | | |
| | | | patient with complications of | | | |
| | | | cirrhosis. | | | |
| | | 6. | Recommend a specific | | | |
| | | | treatment regimen for a | | | |
| | | | patient with cirrhosis that | | | |
| | | | includes lifestyle changes, | | | |
| | | | nonpharmacologic measures, | | | |
| | | | and pharmacologic therapy. | | | |
| 9 | 1 | 1. | Differentiate the five types of | Viral henatitis | Lectures. | Simple |
| | 1 | 1. | | vitai nepatitis. | Simple | - |
| | | | 1 | | discussions. | quizzes. |
| | | | epidemiology, etiology, and | | discussions. | |
| | | | clinical presentation. | | | |
| | | 2. | Identify modes of | | | |
| | | | transmission and risk factors | | | |
| | | | among the major types of | | | |
| | | | viral hepatitis. | | | |
| | | 3. | Evaluate hepatic serologies | | | |
| | | | to understand how the type of | | | |
| | | | hepatitis is diagnosed. | | | |
| | | 4. | Create treatment goals for a | | | |
| | | | patient infected with viral | | | |
| | | | - | | | |
| | | 5. | - | | | |
| | | | 11 1 | | | |
| | | | | | | |
| | | 6 | <u> </u> | | | |
| | | 0. | <u> </u> | | | |
| | | | | | | |
| 10 | 1 | 1 | • | Inflommeters | Lagturas | Cimple |
| 10 | 1 | 1. | | | | - |
| | | | | bower disease. | 1 | quizzes. |
| | | | • • | | discussions. | |
| | | | <u> </u> | | | |
| | | _ | | | | |
| | | 2. | | | | |
| | | | | | | |
| | | | | | | |
| | | | ` , | | | |
| | | | | | | |
| | | 3. | Identify appropriate | | | |
| | | | therapeutic outcomes for | | | |
| | | 1 | patients with IBD. | | | |
| 10 | 1 | 5.6.1.2. | Create treatment goals for a patient infected with viral hepatitis. Recommend appropriate pharmacotherapy for prevention of viral hepatitis. Develop a care plan for treatment of chronic viral hepatitis. Characterize the pathophysiologic mechanisms underlying inflammatory bowel disease (IBD). Recognize the signs and symptoms of IBD, including major differences between ulcerative colitis (UC) and Crohn disease (CD). Identify appropriate therapeutic outcomes for | Inflammatory bowel disease. | Lectures. Simple discussions. | Simple quizzes. |

| | | 5. | Describe pharmacologic treatment options for patients with acute or chronic symptoms of UC and CD. Create a patient-specific drug treatment plan based on symptoms, severity, and location of UC or CD. Recommend appropriate monitoring parameters for drug treatments for IBD. | | | |
|----|---|----|---|---------------------------------------|-------------------------------------|-----------------|
| 11 | 1 | 3. | List the types and etiologies of shock syndromes. Describe the major hemodynamic abnormalities that occur in patients with shock. Describe the clinical presentation including signs, symptoms, and laboratory test measurements for the typical shock patient. Prepare a treatment plan with clearly defined outcome criteria for a shock patient that includes both fluid management and pharmacologic therapy. Compare and contrast relative advantages and disadvantages of crystalloids, colloids, and blood products in the treatment of shock. | Shock syndromes. | Lectures. Simple discussions. | Simple quizzes. |
| 12 | 2 | 2. | Estimate the volumes of various body fluid compartments. Identify the electrolytes primarily found in the extracellular and intracellular fluid compartments. Describe the unique relationship between serum sodium concentration and total body water (TBW). Review the etiology, clinical presentation, and | Disorders of fluids and electrolytes. | Lectures. Simple discussions. | Simple quizzes. |

| | | management for disorders of | | | |
|----|---|---|------------|-----------------------------------|-----------------|
| | | 1 | | | |
| | | sodium, potassium, calcium, | | | |
| 10 | | phosphorus, and magnesium. | D 11 | . | G: 1 |
| 13 | 1 | 1. Describe the epidemiology and social impact of epilepsy. | Epilepsy. | Lectures. Simple | Simple quizzes. |
| | | 2. Define terminology related to | | discussions. | 1 |
| | | epilepsy, including seizure, | | 313 C 33 5 10 115 1 | |
| | | convulsion, and epilepsy. | | | |
| | | 3. Describe the basic | | | |
| | | pathophysiology of seizures | | | |
| | | and epilepsy. | | | |
| | | 4. Differentiate and classify | | | |
| | | seizure types given a | | | |
| | | description of the clinical | | | |
| | | presentation of the seizure | | | |
| | | and electroencephalogram. | | | |
| | | 5. Identify key therapeutic | | | |
| | | decision points and | | | |
| | | therapeutic goals in the | | | |
| | | treatment of epilepsy. | | | |
| | | 6. Discuss nonpharmacologic | | | |
| | | treatments for epilepsy. | | | |
| | | 7. Recommend an appropriate | | | |
| | | pharmacotherapeutic | | | |
| | | regimen with monitoring | | | |
| | | parameters for the treatment | | | |
| | | of epilepsy. | | | |
| | | 8. Devise a plan for switching a | | | |
| | | patient from one antiepileptic | | | |
| | | regimen to a different | | | |
| | | regimen. | | | |
| | | 9. Manage potential drug | | | |
| | | interactions with | | | |
| | | antiepileptic drugs (AEDs). | | | |
| | | 10. Determine when and how to | | | |
| | | discontinue AED therapy. | | | |
| 14 | 1 | 1. Identify risk factors for | Multiple | Lectures. | Simple |
| | | multiple sclerosis (MS). | sclerosis. | Simple | quizzes. |
| | | 2. Distinguish between forms of | | discussions. | 1 |
| | | MS based on patient | | | |
| | | presentation and disease | | | |
| | | course. | | | |
| | | 3. Compare and contrast MS | | | |
| | | <u> </u> | | | |
| | | , , , | | | |
| | | disease-modifying treatment choices for a given patient. | | | |

| | | 1 | Determine | | | |
|----|---|----|--------------------------------|--------------------|--------------|----------|
| | | 4. | Determine appropriate | | | |
| | | | symptomatic treatment | | | |
| | | | choices for a given patient. | | | |
| | | 5. | Develop a monitoring plan | | | |
| | | | for a patient placed on | | | |
| | | | specific medications. | | | |
| 15 | 1 | 1. | Evaluate patient-specific | Enteral nutrition. | Lectures. | Simple |
| | | | parameters to determine | | Simple | quizzes. |
| | | | whether EN is appropriate. | | discussions. | quiezes. |
| | | 2 | Compare clinical efficacy, | | discussions. | |
| | | 2. | 1 | | | |
| | | | complications, and costs of | | | |
| | | | EN versus parenteral | | | |
| | | | nutrition (PN). | | | |
| | | 3. | Describe the components of | | | |
| | | | EN and their role in nutrition | | | |
| | | | support therapy. | | | |
| | | 4 | Develop a plan to design, | | | |
| | | | initiate, and adjust an EN | | | |
| | | | formulation for an adult | | | |
| | | | | | | |
| | | | patient based on patient- | | | |
| | | | specific factors. | | | |
| | | 5. | Describe the etiology and | | | |
| | | | risk factors for EN- | | | |
| | | | associated complications in | | | |
| | | | adult patients receiving EN. | | | |
| | | 6. | Select appropriate | | | |
| | | 0. | medication administration | | | |
| | | | | | | |
| 16 | 1 | 1 | techniques for an EN patient. | Parenteral | Lastinas | Cimanla |
| 10 | 1 | 1. | List appropriate indications | | Lectures. | Simple |
| | | | for parenteral nutrition (PN) | nutrition. | Simple | quizzes. |
| | | | in adult patients. | | discussions. | |
| | | 2. | Describe the components of | | | |
| | | | PN and their role in nutrition | | | |
| | | | support therapy. | | | |
| | | 3. | Develop a plan to design, | | | |
| | | | initiate, and adjust a PN | | | |
| | | | formulation for an adult | | | |
| | | | patient based on patient- | | | |
| | | | specific factors. | | | |
| | | 4 | • | | | |
| | | 4. | ~ · | | | |
| | | | | | | |
| | | | | | | |
| | | | complications in adult | | | |
| | | | patients receiving PN. | | | |
| | | 5. | Describe the etiology and | | | |
| | | | | | | |
| | | | patients receiving PN. | | | |

| | | syndromo os woll os | | | |
|-----|---|---|-------------|--------------|----------|
| | | syndrome, as well as | | | |
| | | measures to prevent refeeding syndrome. | | | |
| 17 | 1 | | Doon warene | Lactures | Cimple |
| 1 / | 1 | 1. Identify risk factors and | Deep venous | Lectures. | Simple |
| | | signs and symptoms of deep | thrombosis. | Simple | quizzes. |
| | | vein thrombosis (DVT) and | | discussions. | |
| | | pulmonary embolism (PE). | | | |
| | | 2. Describe the processes of | | | |
| | | hemostasis and thrombosis. | | | |
| | | 3. Determine a patient's | | | |
| | | relative risk of developing | | | |
| | | venous thrombosis. | | | |
| | | 4. Formulate an appropriate | | | |
| | | prevention strategy for a | | | |
| | | patient at risk for DVT. | | | |
| | | 5. Select and interpret | | | |
| | | laboratory test(s) to monitor | | | |
| | | antithrombotic drugs. | | | |
| | | 6. Identify factors that place a | | | |
| | | patient at high risk of | | | |
| | | bleeding while receiving | | | |
| | | antithrombotic drugs. | | | |
| | | 7. State at least two potential | | | |
| | | advantages of newer | | | |
| | | anticoagulants (ie, low | | | |
| | | molecular weight heparins | | | |
| | | [LMWHs], fondaparinux, | | | |
| | | oral direct thrombin | | | |
| | | inhibitors [DTIs], and oral | | | |
| | | direct factor Xa inhibitors) | | | |
| | | over traditional | | | |
| | | anticoagulants (ie, | | | |
| | | unfractionated heparin and | | | |
| | | warfarin). | | | |
| | | 8. Manage a patient with | | | |
| | | toxicity secondary to | | | |
| | | warfarin (elevated | | | |
| | | international normalized | | | |
| | | ratio [INR] with or without | | | |
| | | bleeding). | | | |
| | | 9. Identify anticoagulant drug— | | | |
| | | drug and drug-food | | | |
| | | interactions. | | | |
| | | 10. Formulate an appropriate | | | |
| | | treatment plan for a patient | | | |
| | | who develops a DVT or PE. | | | |

| 18 | 2 | 1. De | scribe the phases | of | Arrhythmias. | Lectures. | Simple |
|----------|---|--------|---|--------|---|--|----------|
| | _ | | diac action potential. | 01 | 1 11 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Simple | quizzes. |
| | | | scribe the modif | ied | | discussions. | quinne |
| | | | ughan Willia | | | G 10 G 0 0 0 10 110 . | |
| | | | ssification | of | | | |
| | | | iarrhythmic drugs. | OI | | | |
| | | | • | siolz. | | | |
| | | | mpare and contrast tors for and feature | | | | |
| | | | | - | | | |
| | | | chanisms, etiolog | | | | |
| | | _ | nptoms, and goals | | | | |
| | | | 1 2 | nus | | | |
| | | | dycardia, | (b) | | | |
| | | | ioventricular (AV) blo | | | | |
| | | | atrial fibrillation (AF), | | | | |
| | | _ | oxysmal supraventricu | | | | |
| | | | • | (e) | | | |
| | | _ | emature ventricu | | | | |
| | | | mplexes (PVCs), | (f) | | | |
| | | | ntricular tachycardia (V | | | | |
| | | | luding torsades de poir | | | | |
| | | [To | dP]), and (g) ventricu | ılar | | | |
| | | fib | rillation (VF). | | | | |
| | | 4. Co | mpare and conti | ast | | | |
| | | app | propriate treatment option | ons | | | |
| | | for | sinus bradycardia and a | AV | | | |
| | | blo | ck. | | | | |
| | | 5. Co | | | | | |
| | | me | chanisms of action | of | | | |
| | | dru | igs used for ventricu | ılar | | | |
| | | rat | e control, conversion | to | | | |
| | | sin | us rhythm a | and | | | |
| | | ma | intenance of sinus rhyt | hm | | | |
| | | in 1 | patients with AF. | | | | |
| | | 6. Co | mpare and contrast | the | | | |
| | | | | and | | | |
| | | dis | advantages of warfa | rin | | | |
| | | and | d the non-vitamin | K | | | |
| | | ant | agonist | oral | | | |
| | | | icoagulants (NOACs) | for | | | |
| | | | | and | | | |
| | | | stemic embolism | in | | | |
| | | | ients with AF. | | | | |
| | | 7. Dis | | gic | | | |
| | | | thods for termination | _ | | | |
| | | | VT, compare and contr | | | | |
| | | | chanisms of action | | | | |
| <u> </u> | I | 1110 | 31 33 31 31 31 | | | | |

| 19 | 2 | drugs used for acute termination of PSVT, and compare and contrast appropriate treatment options for long-term prevention of PSVT recurrence. 8. Compare and contrast mechanisms of action of drugs used for treatment of acute episodes of VT, and describe options and indications for nonpharmacologic treatment of VT and VF. 9. Design individualized drug therapy treatment plans for patients with (a) sinus bradycardia, (b) AV block, (c) AF, (d) PSVT, (e) PVCs, (f) VT (including TdP), and (g) VF. 1. Identify characteristics of the | Pain | Lectures. | Simple |
|----|---|---|------|---------------------|----------|
| | | types of pain: nociceptive, inflammatory, neuropathic, and functional. 2. Explain the mechanisms involved in pain transmission. 3. Select an appropriate method of pain assessment. 4. Recommend an appropriate choice of analgesic, dose, and monitoring plan for a patient based on type and severity of pain and other patient-specific parameters. 5. Perform calculations involving equianalgesic doses, conversion of one opioid to another, rescue doses, and conversion to a continuous infusion. 6. Educate patients and caregivers about effective pain management, dealing with chronic pain, and the use | | Simple discussions. | quizzes. |

| | | of nonpharmacologic | | | |
|----|---|--|----------------------|-------------------------------|-----------------|
| | | measures. | | | |
| 20 | 1 | Differentiate types of headache syndromes based on clinical features. Recommend nonpharmacologic measures for headache treatment and prevention. Determine when the pharmacologic treatment of headache is indicated. Construct individualized treatment regimens for the acute and chronic management of headache | Headache. | Lectures. Simple discussions. | Simple quizzes. |
| | | syndromes. 5. Monitor headache treatment to ensure its safety, tolerability, and efficacy. | | | |
| 21 | 2 | Describe the pathophysiology of Parkinson disease (PD) related to neurotransmitter involvement and targets for drug therapy. Recognize the cardinal motor symptoms of PD and determine a patient's clinical status and disease progression. For a patient initiating therapy for PD, recommend appropriate drug therapy and construct patient- specific treatment goals. Recognize and recommend appropriate treatment for nonmotor symptoms. Formulate a plan to minimize patient "off-time" and maximize "on-time" including timing, dosage, and frequency of medications. Recognize and treat various motor complications in PD. | Parkinson's disease. | Lectures. Simple discussions. | Simple quizzes. |

| | | 7 0 | | | |
|----|---|-------------------------------------|------------------|--------------|----------|
| | | 7. Construct appropriate patient | | | |
| | | counseling regarding | | | |
| | | medications and lifestyle | | | |
| | | modifications for PD. | | | |
| | | 8. Develop a monitoring plan to | | | |
| | | assess effectiveness and | | | |
| | | adverse effects of treatment. | | | |
| 22 | 1 | 1. Explain the pathophysiology | Benign prostatic | Lectures. | Simple |
| | | of benign prostatic | hyperplasia. | Simple | quizzes. |
| | | hypertrophy (BPH). | | discussions. | - |
| | | 2. Recognize the symptoms and | | | |
| | | signs of BPH. | | | |
| | | 3. List the desired treatment | | | |
| | | outcomes for BPH. | | | |
| | | | | | |
| | | 4. Identify factors that guide | | | |
| | | selection of a particular α1- | | | |
| | | adrenergic antagonist for an | | | |
| | | individual patient. | | | |
| | | 5. Compare and contrast α 1- | | | |
| | | adrenergic antagonists versus | | | |
| | | 5α-reductase inhibitors in | | | |
| | | terms of mechanism of | | | |
| | | action, treatment outcomes, | | | |
| | | adverse effects, and | | | |
| | | interactions. | | | |
| | | 6. Describe the indications, | | | |
| | | advantages, and | | | |
| | | disadvantages of various | | | |
| | | combination drug regimens | | | |
| | | that include an α1-adrenergic | | | |
| | | antagonist, 5α-reductase | | | |
| | | , | | | |
| | | inhibitor, anticholinergic | | | |
| | | agent, tadalafil, or | | | |
| | | mirabegron. | | | |
| | | 7. Describe the indications for | | | |
| | | surgical intervention. | | | |
| | | 8. Apply the patient care | | | |
| | | process to develop an | | | |
| | | individualized treatment | | | |
| | | plan. | | | |
| 23 | 1 | 1. Identify risk factors for the | Glaucoma. | Lectures. | Simple |
| | | development of primary | | Simple | quizzes. |
| | | open-angle glaucoma | | discussions. | |
| | | (POAG) and acute angle- | | | |
| | | closure glaucoma. | | | |
| L | | Jiobaro Simocomia. | I | | |

| | l | 1 a a a | |
|---------|-----------|------------------------------------|---|
| | | 2. Recommend a frequency for | |
| | | glaucoma screening based on | |
| | | patient-specific risk factors. | |
| | | 3. Compare and contrast the | |
| | | pathophysiologic | |
| | | mechanisms responsible for | |
| | | open-angle glaucoma and | |
| | | acute angle-closure | |
| | | glaucoma. | |
| | | 4. Outline the clinical | |
| | | presentation of chronic open- | |
| | | angle glaucoma and acute | |
| | | angle-closure glaucoma. | |
| | | 5. List the goals of managing | |
| | | patients with POAG suspect, | |
| | | POAG, and acute angle- | |
| | | closure glaucoma. | |
| | | 6. Choose the most appropriate | |
| | | therapy based on patient- | |
| | | specific data for open-angle | |
| | | glaucoma, glaucoma suspect, | |
| | | and acute angle-closure | |
| | | glaucoma. | |
| | | 7. Develop a monitoring plan | |
| | | for patients on specific | |
| | | pharmacologic regimens. | |
| | | 8. Counsel patients about | |
| | | glaucoma, drug therapy | |
| | | options, ophthalmic | |
| | | administration techniques, | |
| | | and the importance of | |
| | | adherence to the prescribed | |
| | | regimen. | |
| ✓ Co | urse Eva | aluation | |
| Midtern | n exam 2 | 25 marks, Quizzes and attendance 5 | marks, Final exam 70 marks |
| | | nd Teaching Resources | |
| Require | a textboo | oks (curricular books, if any) | Pharmacotherapy: A pathophysiologic |
| | | | approach. |
| | | | Pharmacotherapy: principles and practice. |
| | | | Applied therapeutics. |
| | | | Clinical pharmacy and therapeutics. |
| | | | Pharmacotherapy handbook. |
| 3.6 : | C | | ACCP updates in therapeutics. |
| Main re | terences | (sources) | Pharmacotherapy: A pathophysiologic |
| | | | approach. |

| | Pharmacotherapy: principles and practice. | | | | |
|--|---|--|--|--|--|
| | Applied therapeutics. | | | | |
| | ACCP updates in therapeutics. | | | | |
| Recommended books and references (scientific | Pharmacotherapy: A pathophysiologic | | | | |
| journals, reports) | approach. | | | | |
| | Pharmacotherapy: principles and practice. | | | | |
| Electronic References, Websites | Electronic books and review articles. | | | | |

Course Description Form

| \checkmark | Course | Name: | | | | |
|--------------|-----------|---------------------------|------------|--|--|--|
| Ap | plied T | herapeutics II | | | | |
| ✓ | Course | Code: | | | | |
| 565 C | oAt2 | | | | | |
| ✓ | Semest | er / Year: | | | | |
| Seco | nd sem | ester/ Fifth | | | | |
| ✓ | Descrip | otion Preparation Date: | | | | |
| 17 - | - 02 - 20 |)24 | | | | |
| ✓ | Availal | ole Attendance Forms: | | | | |
| | On can | ıpus | | | | |
| ✓ | Numbe | r of Credit Hours (Total) | / Numbe | er of Units (Total) | | |
| 2 Hour | s /2 Uni | its | | | | |
| ✓ | Course | administrator's name (me | ention all | , if more than one | name) | |
| | Name: | Ehab Mudher Mikhael an | ıd Samer | Imad Mohammed | 1 | |
| | Email: | ihab.maddr@copharm.uo | baghdad | <u>.edu.iq</u> & | | |
| | | ameel@copharm.uobagh | dad.edu.i | iq | | |
| | | Objectives | | | | |
| | - Objec | ng and Learning Strategie | • | treatment for gynecological, disorders It provides stude about medications side effects, | siology, symptom some cancers, psychiatric, and ents with the base ons use, dose contreatment algo- therapeutic outcome | s and aims of endocrine, neurological ic knowledge onsiderations, orithms and |
| | | Lectures | S | | | |
| Strateg | зу | Seminars | | | | |
| | | Simple quizzes | | | | |
| | | Brainstorming que | estions | | | |
| ✓ C | ourse Si | tructure | 75010115 | | | |
| Week | Hours | | ing | Unit or | Learning | Evaluation |
| | | | | | | |

| 1 | 1 | 1. | Explain the regulation | Adrenal | Lectures | Simple |
|---|---|-----|--|-----------|-------------|---------|
| | | | and physiologic roles of | gland | and | quizzes |
| | | | hormones produced by the adrenal glands. | disorders | Discussions | |
| | | 2 | Recognize the clinical | | | |
| | | | presentation of adrenal | | | |
| | | | insufficiency. | | | |
| | | 3. | Describe the | | | |
| | | | pharmacologic | | | |
| | | | management of acute and chronic adrenal | | | |
| | | | insufficiency. | | | |
| | | 4. | Recommend therapy | | | |
| | | | monitoring parameters for adrenal insufficiency. | | | |
| | | 5. | Recognize the clinical | | | |
| | | | presentation of Cushing | | | |
| | | | syndrome and the | | | |
| | | | physiologic consequences of cortisol excess. | | | |
| | | 6. | Describe the | | | |
| | | | pharmacologic and | | | |
| | | | nonpharmacologic | | | |
| | | | management of Cushing | | | |
| | | 7 | syndrome. Recommend strategies to | | | |
| | | ′ · | prevent the development | | | |
| | | | of hypercortisolism and | | | |
| | | | hypocortisolism. | | | |
| | | 8. | Recommend therapy | | | |
| | | | monitoring parameters for Cushing syndrome. | | | |
| 2 | 2 | 1. | Explain the major | Thyroid | Lectures | Simple |
| | | | components of the | gland | and | quizzes |
| | | | hypothalamic-pituitary- | disorders | Discussions | |
| | | | thyroid axis and | | | |
| | | | interaction among these components. | | | |
| | | 2 | Discuss the relationship | | | |
| | | | between serum thyroid- | | | |
| | | | stimulating hormone | | | |
| | | | (TSH) levels and primary | | | |
| | | | thyroid disease, and | | | |
| | | | advantages for the use of TSH levels over other | | | |
| | | | tests such as serum T4 | | | |
| L | 1 | 1 | | | | |

| | Т | 1 | | | | |
|---|---|----|-----------------------------|-----------|-------------|---------|
| | | | (thyroxine) and T3 | | | |
| | | | (triiodothyronine) levels. | | | |
| | | | Identify typical signs and | | | |
| | | | symptoms of | | | |
| | | | hypothyroidism and | | | |
| | | | consequences of | | | |
| | | | suboptimal treatment. | | | |
| | | 4. | Describe clinical use of | | | |
| | | | levothyroxine (LT4) in | | | |
| | | | the treatment of | | | |
| | | | hypothyroidism. | | | |
| | | 5. | Discuss issues regarding | | | |
| | | | LT4 product | | | |
| | | | bioequivalence and | | | |
| | | | reasons for maintaining | | | |
| | | | patients on the same | | | |
| | | | product. | | | |
| | | 6. | Describe the management | | | |
| | | | of hypothyroidism and | | | |
| | | | hyperthyroidism in | | | |
| | | | special populations, | | | |
| | | | including pregnant | | | |
| | | | women. | | | |
| | | 7. | Identify typical signs and | | | |
| | | | symptoms of | | | |
| | | | hyperthyroidism and | | | |
| | | | consequences of | | | |
| | | | inadequate treatment. | | | |
| | | 8. | Discuss the | | | |
| | | | pharmacotherapy of | | | |
| | | | hyperthyroidism, | | | |
| | | | including advantages and | | | |
| | | | disadvantages of | | | |
| | | | antithyroid drugs versus | | | |
| | | | radioactive iodine, | | | |
| | | | adverse effects, and | | | |
| | | | patient monitoring. | | | |
| 3 | 1 | 1. | Describe the | Alzheimer | Lectures | Simple |
| | | | pathophysiology, | disease | and | quizzes |
| | | | including genetic and | | Discussions | |
| | | | environmental factors that | | | |
| | | | may be associated with | | | |
| | | | AD. | | | |
| | | | Detail the clinical | | | |
| | | | presentation of the typical | | | |
| | | | patient with AD. | | | |
| | | | · | | | |

| | | 4. | Explain how nonpharmacologic therapy is combined with pharmacologic therapy for patients with AD. Recognize and recommend treatment options for disease-specific symptoms as well as behavioral/noncognitive symptoms associated with AD. Educate patients and/or caregivers about the expected outcomes for patients with AD and provide contact information for support/advocacy agencies. | | | |
|---|---|--|--|----------------|--------------------------------|----------------|
| 4 | 2 | 3. 4. 5. | Recognize signs and symptoms of schizophrenia Explain potential pathophysiologic mechanisms that are thought to underlie schizophrenia. Identify treatment goals for a patient with schizophrenia. Recommend appropriate antipsychotic medications based on patient-specific data. Compare side effect profiles of individual antipsychotics. Educate patients and families about schizophrenia, treatments, and the importance of adherence to antipsychotic treatment. | Schizophre nia | Lectures and Discussions | Simple quizzes |

| 5 | 2 | 1. Explain the etiology and | Depressive | Lectures | Simple |
|---|---|---|----------------------------------|--------------------------------|-------------------|
| | | pathophysiology of major depressive disorder (MDD). 2. Identify the signs and symptoms of MDD. 3. Outline the treatment goals for a patient with MDD. 4. Recommend pharmacotherapy given a specific patient with MDD. 5. Develop a monitoring plan for a specific patient with MDD that includes the assessment of efficacy as well as adverse effects. 6. Educate patients and caregivers on the proper use of antidepressant | disorders | and Discussions | quizzes |
| 6 | 1 | therapy. 1. Explain the pathophysiologic mechanisms underlying anxiety disorders. 2. Recognize common presenting symptoms of generalized anxiety disorder (GAD) 3. List treatment goals for patients with GAD. 4. Identify appropriate lifestyle modifications and over-the-counter medication use in these patients. 6. Design a patient-specific pharmacotherapy treatment plan for patients. 7. Develop a monitoring plan for patients with anxiety disorders. | Anxiety | Lectures and Discussions | Simple quizzes |
| 7 | 1 | 1. Describe the pathophysiolog and characteristic features of the insomnia. | Sleep disorders (insomnia) | Lectures and Discussions | Simple quizzes |

| | Recommend and optimize appropriate sleep hygiene and nonpharmacologic therapies for the management and prevention of sleep disorders. Recommend and optimize appropriate pharmacotherapy for insomnia. Describe the components of the patient care process to implement and assess safety and efficacy of pharmacotherapy for insomnia. | | | |
|-----|---|-------------|--------------------------|----------------|
| 8 1 | Discuss the physiology of the female reproductive system. Compare the efficacy of oral contraceptives with that of other methods of contraception. State the mechanism of action of hormonal contraceptives. Discuss adverse effects, risks, and contraindications associated with the use of contraceptives and recommend strategies for minimizing or eliminating such risks. Describe advantages and disadvantages of various contraceptives, including oral and nonoral formulations. Cite important drug interactions that may occur with oral contraceptives. Provide appropriate patient education regarding the use of oral | Contracepti | Lectures and Discussions | Simple quizzes |

| | | | and barrier methods of | | | |
|----|---|----|--|-------------|-------------|---------|
| | | | contraception. | | | |
| | | 8. | Discuss how emergency | | | |
| | | | contraception may be | | | |
| | | | employed to prevent | | | |
| | | | unintended pregnancy. | | | |
| 9 | 2 | 1. | Explain the physiologic | Hormone | Lectures | Simple |
| | | | changes associated with | replacement | and | quizzes |
| | | | menopause. | therapy in | Discussions | |
| | | 2. | Identify the signs and | post | | |
| | | | symptoms associated with | menopausal | | |
| | | | menopause. | women | | |
| | | 3. | Determine the desired | | | |
| | | | therapeutic outcomes for | | | |
| | | | patients taking | | | |
| | | | menopausal hormone | | | |
| | | | replacement therapy | | | |
| | | | (MHRT). | | | |
| | | 4. | Explain how to evaluate a | | | |
| | | | patient for the appropriate use of MHRT. | | | |
| | | _ | | | | |
| | | ٥. | Recommend appropriate nonpharmacologic and | | | |
| | | | pharmacologic and | | | |
| | | | interventions for | | | |
| | | | menopausal symptoms. | | | |
| | | 6 | Design a monitoring plan | | | |
| | | 0. | to assess the safety and | | | |
| | | | effectiveness of | | | |
| | | | pharmacotherapy | | | |
| 10 | 1 | 1. | Describe the underlying | Menstruatio | Lectures | Simple |
| | | 1. | etiology of | n related | and | quizzes |
| | | | dysmenorrhea, | disorders | Discussions | 40 |
| | | | amenorrhea, and | | | |
| | | | anovulatory bleeding. | | | |
| | | 2. | Explain the physiologic | | | |
| | | | changes associated with | | | |
| | | | dysmenorrhea, | | | |
| | | | amenorrhea, and | | | |
| | | | anovulatory bleeding. | | | |
| | | 3. | Identify the signs and | | | |
| | | | symptoms associated | | | |
| | | | with dysmenorrhea, | | | |
| | | | amenorrhea, and | | | |
| | | | anovulatory bleeding. | | | |

| | | Determine the desired therapeutic outcomes for patients with dysmenorrhea, amenorrhea, and anovulatory bleeding. Recommend appropriate nonpharmacologic and pharmacologic interventions for dysmenorrhea, amenorrhea, and anovulatory bleeding. Design a monitoring plan to assess the safety and effectiveness of pharmacotherapy. | | | |
|----|---|---|---|--------------------------------|-------------------|
| 11 | 2 | Describe the pathophysiology of cancer. Define the tumor, nodes, metastases (TNM) system of cancer staging. Define prevention and treatment strategies of cancer. Outline actions for all healthcare professionals to prevent medication errors with cancer treatments. | Cancer chemothera py and treatment | Lectures and Discussions | Simple quizzes |
| 12 | 2 | Explain the pathophysiology of certain types of leukemia. Explain the signs/symptoms and laboratory disorders associated with leukemias. Identify underlying considerations that would determine the most appropriate chemotherapeutic regimens for patients having leukemia. | Leukemias | Lectures and Discussions | Simple quizzes |

| | | 5. Ro | escribe the available eatment options of ertain types of leukemias ecognize the treatment omplications associated ith the therapy of ukemias. | | | |
|----|---|--|---|------------------|--------------------------------|-------------------|
| 13 | 1 | 2. Rosy and di 3. Doan fa | explain the risk factors associated with eveloping breast cancer. ecognize signs and emptoms related to early ad late stages of the assease. istinguish between good and poor prognostic actors. etermine treatment | Breast cancer | Lectures and Discussions | Simple quizzes |
| | | section for the section of the secti | cals for early-stage, cally advanced, and etastatic breast cancers. explain the available eatment options of reast cancer. | | | |
| | | ho 1 : | escribe the relevance of prmone, HER2, and PD-receptors. iscuss the benefits and | | | |
| | | ris | sks associated with arious therapies. | | | |
| 14 | 1 | 1. Id | lentify risk factors sociated with prostate uncer development. | Prostate cancer | Lectures and Discussions | Simple quizzes |
| | | an ne ap | ppraise the prognostic- nd patient-specific data eeded to determine opropriate treatment otions. | | | |
| | | pł tro di | valuate narmacotherapeutic eatment options for fferent types of prostate uncer. | | | |
| | | | ecognize common lverse effects and | | | |

| | | formulate a monitoring plan for patients receiving androgen deprivation therapy for prostate cancer based on patient-specific factors and the prescribed regimen. 5. Recognize the common adverse effects and formulate a monitoring plan for patients receiving treatment for metastatic prostate cancer. 6. Provide recommendations for bone health for patients undergoing treatment for prostate cancer. | | | |
|----|---|--|---|--------------------------------|-------------------|
| 15 | 1 | Introduction about common and problematic adverse effect of chemotherapy Recognizing the clinically significant adverse effects Explaining the preventive measures of certain adverse effects Discussing the available therapeutic options of some adverse effects. | Adverse effects of chemothera py | Lectures and Discussions | Simple quizzes |
| 16 | 2 | 1. Explain the pathophysiologic mechanisms underlying bipolar disorder. 2. Recognize the symptoms of a manic episode in patients with bipolar disorder. 3. Identify common psychiatric comorbidities of bipolar disorder. | Bipolar disorders | Lectures and Discussions | Simple quizzes |

| | | 4. List the desired therapeutic outcomes for patients with bipolar disorder. 5. Identify the optimal use of medications as first-line therapy in bipolar disorder, including appropriate dosing. 6. Recommend drug therapy for acute treatment of mania and depressive episodes. 7. Recommend baseline and routine monitoring for assessment of adverse effects of medications used in the treatment of bipolar disorder. 8. Identify general treatment differences for agents used to treat bipolar disorder in the pediatric population. | | | |
|----|---|--|-------------------|--------------------------------|----------------|
| 17 | 1 | Identify the risk factors for colorectal cancer. Outline preventive and screening strategies for individuals at average and high risk for colorectal cancer. Recognize the signs and symptoms of colorectal cancer. Describe the treatment options for colorectal cancer based on patient-specific factors, such as stage of disease, age of patient, genetic mutations, and previous treatment received. | Colorectal cancer | Lectures and Discussions | Simple quizzes |

| | | 7. | Outline the pharmacologic principles for agents used to treat colorectal cancer. Develop a monitoring plan to assess the efficacy and toxicity of agents used in colorectal cancer. Educate patients about the adverse effects of chemotherapy that require specific patient counseling. | | | |
|----|---|--|--|--|--------------------------------|-------------------|
| 18 | 2 | 3. 4. 5. | Explain the routes of transmission for human immunodeficiency virus (HIV) and its natural disease progression. Identify typical and atypical signs and symptoms of acute and chronic HIV infection. Identify the desired therapeutic outcomes for patients living with HIV. Recommend appropriate first-line pharmacotherapy interventions for patients with HIV infection. Describe the components of a monitoring plan to assess effectiveness and adverse effects of pharmacotherapy for HIV infection. Educate patients about the disease state, appropriate lifestyle modifications, and drug therapy required for effective treatment. | Human immunodefi ciency virus | Lectures and Discussions | Simple quizzes |
| 19 | 2 | 1. | Discuss the underlying pathophysiologic mechanisms of the lymphomas and how they | Lymphoma and multiple myeloma | Lectures and Discussions | Simple quizzes |

| | | relate to presenting | | |
|---|----|--|--|--|
| | | symptoms of the disease. | | |
| | 2. | Differentiate the | | |
| | | pathologic findings of | | |
| | | Hodgkin lymphoma | | |
| | | (HL), follicular indolent | | |
| | | non-Hodgkin lymphoma | | |
| | | (NHL), and diffuse | | |
| | | aggressive NHL and how | | |
| | | this information yields a | | |
| | _ | specific diagnosis. | | |
| | 3. | Describe the general | | |
| | | staging criteria for the | | |
| | | lymphomas and how it | | |
| | | relates to prognosis; evaluate the role of the | | |
| | | prognostic systems such | | |
| | | as the International | | |
| | | Prognostic Score for HL, | | |
| | | the Follicular Lymphoma | | |
| | | International Prognostic | | |
| | | Index (IPI), and the IPI | | |
| | | for diffuse, aggressive | | |
| | | NHL. | | |
| | 4. | Compare and contrast the | | |
| | | treatment algorithms for | | |
| | | early and advanced stage | | |
| | | disease for HL. | | |
| | 5. | Assess the role of | | |
| | | autologous hematopoietic | | |
| | | stem-cell transplantation | | |
| | _ | for relapsed lymphomas. | | |
| | 6. | Delineate the clinical | | |
| | | course of follicular | | |
| | | indolent and diffuse aggressive NHL and the | | |
| | | implications for disease | | |
| | | classification schemes | | |
| | | and treatment goals. | | |
| | 7 | Outline the general | | |
| | • | treatment approach to | | |
| | | follicular indolent and | | |
| | | diffuse aggressive NHL | | |
| | | for localized and | | |
| | | advanced disease. | | |
| L | | | | |

| | | 8. Interpret the current refor monoclonal antibo | | | |
|----------------------------------|------------|--|---------------------------------|--------------------------------|-------------------|
| | | therapy in NHL. | | | |
| 20 | 1 | Explain the pathophysiology of Endometriosis. Explain the signs/symptoms of Endometriosis. Outling the general | Endometrio sis | Lectures and Discussions | Simple quizzes |
| | | 3- Outline the general treatment approach | | | |
| ✓ C | ourse Eva | aluation | - | | |
| Midter | m exam 2 | 25 marks, Quizzes and atter | ndance 5 marks, Final e | exam 70 marks | |
| ✓ L | earning a | nd Teaching Resources | | | |
| Require | ed textbo | oks (curricular books, if an | Pharmacothera | py Handbook | |
| Main references (sources) | | | 1- ACCP Updates in Therapeutics | | |
| | | | 2- Applied therapeutics | | |
| Recommended books and references | | | Review articles | S | |
| (scienti | fic journa | als, reports) | | | |
| Electro | nic Refer | rences, Websites | Medscape | | |

Course Description Form

| ✓ Course Name: |
|---|
| Pharmacoeconomics |
| ✓ Course Code: |
| 563 GP |
| ✓ Semester / Year: |
| 2 nd semester/ 5 th year students |
| ✓ Description Preparation Date: |
| Feb 19, 2024 |
| ✓ Available Attendance Forms: |
| Class attendance (on-campus) |
| ✓ Number of Credit Hours (Total) / Number of Units (Total) |
| 2 hours/2 Units |
| ✓ Course administrator's name (mention all, if more than one name) |
| Name of the First instructor of the Course: Dr. Ali Azeez Al-Jumaili |
| Academic Rank: Associate Professor |
| Degree: PhD |
| E-mail: ali.baraak@copharm.uobaghdad.edu.iq |
| |
| Name of the second instructor of the Course: Dr. Mohammed Yawuz Jamal |
| Academic Rank: Lecturer |
| Degree: Board in Clinical Pharmacy |

E-mail: mohammed.ahmed@copharm.uobaghdad.edu.iq

Name of the third: Ali Lateef Jasim

Academic Rank: Lecturer

Degree: PhD

E-mail: ali.jassem@copharm.uobaghdad.edu.iq

✓ Course Objectives

Course Objectives

Course Objectives

✓ Teaching and Learning Strategies

Strategy Strategy

| ✓ Course | Structure |
|----------|-----------|
|----------|-----------|

| Week | Hours | Required Learning | Unit or subject | Learning | Evaluation |
|------|-------|---|---|---|----------------|
| | | Outcomes | name | method | method |
| 1 | 4 | 1. Introduce Pharmacoeconomic principles. 2. Demonstrate types of healthcare costs with examples 3. Learn about ECHO model for the 3 patient outcome types. 4. Explain and differentiate among the 4 methods of Pharmacoeconomic analyses. | Basic principle of Pharmacoeconomics | | Simple quizzes |
| 2 | 4 | 1. Identifying costs 2. Types of costs (Direct Medical Costs, Direct Nonmedical Costs, Indirect costs, Intangible costs) 3. Incremental costs and marginal costs 4. Opportunity costs 5. How are costs valued? Timing Adjustments for Costs | Cost analysis | Interactive lectures and related articles | Simple quizzes |
| 3 | 4 | Understand the Costeffectiveness analysis Outcome measures in cost-effectiveness analysis | Cost-minimizing analysis and Cost effectiveness analyses (CEA). | Interactive lectures and related articles | Simple quizzes |

| | | 3. Knowing how to | | | |
|---|---|---|------------------------|-------------|---------|
| | | calculate Cost- | | | |
| | | effectiveness Ratios | | | |
| 4 | 4 | 1. Understand the Cost- | Cost-benefit analysis | Interactive | Simple |
| 4 | 4 | Benefit Analysis method. | (CBA) | lectures | - |
| | | <u> </u> | (CDA) | and related | quizzes |
| | | 2. Knowing how to calculate the indirect cost | | and related | |
| | | | | articles | |
| | | of the disease and indirect | | | |
| | | benefit of the | | | |
| | | intervention/program | | | |
| | | using Human Capital | | | |
| | | Method (HCM). | | | |
| | | 3. Using HCM to | | | |
| | | calculate Daily wage rate | | | |
| | | and Missed days to find | | | |
| | | out the indirect benefit of | | | |
| | | the | | | |
| | | intervention/management. | | | |
| | | 4. Describe in details | | | |
| | | Willingness-to-Pay | | | |
| | | Method (WTP): | | | |
| | | Hypothetical Scenario & | | | |
| | | Bidding Vehicles | | | |
| | | 5. Formats for | | | |
| | | presenting Cost-Benefit | | | |
| | | Analysis (CBA) | | | |
| | | When should we select | | | |
| | | Cost-Benefit or Cost- | | | |
| | | Effectiveness Analysis? | | | |
| 5 | 4 | 1. Use of decision | Critical assessment of | Interactive | Simple |
| | | analysis to design | economic evaluation | lectures | quizzes |
| | | economic evaluations | | and related | |
| | | 2. Decision Analysis | | articles | |
| | | Structure or tree | | | |
| | | 1 5 7 7 7 | D 0 : | | a |
| | | 1. Define Cost of illness | Drug-focused versus | Interactive | Simple |
| 6 | 4 | 2. Knowing how to | disease-focused frame | lectures | quizzes |
| | | calculate Cost of illness | work for conducting | and related | |
| | | 3. Understand the | Pharmacoeconomic | articles | |
| | | difference between | analyses. | | |
| | | healthcare costs and Cost | | | |
| | | of illness | | | |
| | | the students should be all | Intro duction | Intonosti | Cime1. |
| 7 | 4 | the students should be able | Introduction to | Interactive | Simple |
| | | to: | epidemiology. | lectures | quizzes |

| | | | e epidemiology, | | and related | | | | | | |
|--|---------------------|---|--|--|------------------|--------------|--|--|--|--|--|
| | | describe | basic | | articles | | | | | | |
| | | | gy and concepts | | | | | | | | |
| | | of epidem | | | | | | | | | |
| | | | ify types of data | | | | | | | | |
| | | sources. | ify bosis | | | | | | | | |
| | | 3. ident | ify basic of data collection | | | | | | | | |
| | | and interp | | | | | | | | | |
| | | | | Project | | Presentation | | | | | |
| | 2 | Cost-Effectiveness project can be assigned to teach | | presentation. | | skills | | | | | |
| | | students how to | | presentation. | | SKIIIS | | | | | |
| | | understand the | | | | | | | | | |
| 8 | | terminologies used in | | | | ļ | | | | | |
| | | published | - | | | | | | | | |
| | | Pharmaco | economic | | | | | | | | |
| | | studies. | | | | | | | | | |
| | ✓ Course Evaluation | | | | | | | | | | |
| 5 points for quizzes, 5 points for assignments, 20 points for midterm exam and 70 points for the final | | | | | | | | | | | |
| exam | | | | | | | | | | | |
| | | nd Teaching F | | | | | | | | | |
| Require | | textbooks | Bootman JL, Townsend RJ, McGhan WF, (Eds.), Principles | | | | | | | | |
| (curricular books, if any) | | | Pharmacoeconomics, 2nd ed., Harvey Whitney Books Compa | | | | | | | | |
| | | | Cincinnati, Oh, latest edition | | | | | | | | |
| | | | Danéa I.C. Amald Dhamasasasasanias Fram Theory to | | | | | | | | |
| | | | Renée J.G. Arnold. Pharmacoeconomics From Theory to Practice. Second Edition, 2021. CRC Press, | | | | | | | | |
| | | | Boca Raton, FL, USA | | | | | | | | |
| Main re | eferences | (sources) | Hasan Raid, Ali Azeez Al-Jumaili , Nizar Abdulateef Al Ani. Refere | | | | | | | | |
| 1,10,11111 | | (5001005) | Infliximab (Remicade) compared to its biosimilar (Remsima) in patie | | | | | | | | |
| | | | with Ankylosing spondylitis: A Field-based Pharmacoeconomic study. | | | | | | | | |
| | | | Kindy College Medical Journal. April 30, 2023:19 | | | | | | | | |
| | | | https://doi.org/10.47723/kcmj.v19i1.908 | | | | | | | | |
| | | | | | | | | | | | |
| | | | Hasan Raid Fadhil, Ali Azeez Al-Jumaili, and Nizar Abdulateef Al A | | | | | | | | |
| | | | Cost-effectiveness Analysis of Reference Infliximab (Remica | | | | | | | | |
| | | | Compared to its Biosimilar (Remsima) in Iraqi Patients with Rheumat | | | | | | | | |
| | | | | ritis. Iraqi J Pharm Sci, Vol.31(Suppl.) 20 s://doi.org/10.31351/vol31issSuppl.pp100-110 | | | | | | | |
| | | | nups://doi.org/10 | <i>J.</i> 51551/v0151188 5 uppl.p | <u> p100-110</u> | | | | | | |
| Recomi | mended | books and | Value in Health | Iournal | | | | | | | |
| reference | | (scientific | Value in Health Journal ScienceDirect.com by Elsevier | | | | | | | | |
| | s, reports | ` | · uiuo iii iiouitii | - Committee Described Free Committee | | | | | | | |
| | , r - | , | | | | | | | | | |
| Value in Health Journal Regional Issues | | | | | | | | | | | |
| | | | https://www.valuehealthregionalissues.com/ | | | | | | | | |

| Electronic | References, | Value in Health Journal and Value in Health Journal Regional Issu |
|------------|-------------|---|
| Websites | | |

| ✓ Course Na | ame. | | | | |
|-------------------------|---|----------------------|-----------------|-------------------|--|
| Therapeutic drug | | | | | |
| ✓ Course Co | <u> </u> | | | | |
| 566 CpTd | | | | | |
| ✓ Semester | / Year: | | | | |
| Second semester | | | | | |
| | on Preparation Date: | | | | |
| 16-2-2024 | n i reputation Bute. | | | | |
| | Attendance Forms: | | | | |
| On camp | | | | | |
| | f Credit Hours (Total) / Number of | of Units (Total) | | | |
| 4Hours / | · / | (1000) | | | |
| ✓ Course ad | ministrator's name (mention all, if | f more than one name |) | | |
| | ssistant Professor Dr. Samer Imac | | | | |
| Email: sa | amer.jameel@copharm.uobaghda | d.edu.iq | | | |
| | ecturer Dr. Basma Zuheir Muham | | | | |
| Email: ba | asma.naji@copharm.uobaghdad.eo | du.iq | | | |
| | | • | | | |
| ✓ Course Ol | ojectives | | | | |
| Course Objective | Course Objectives At the end of this unit, the student should be able to: recognize characteristics of drugs that make them good candidates for TDM, describ appropriate indications for TDM, understand the factors that may affect the measured concentrations list, and discuss the importance of information needed when requesting drug concentration interpret measured drug concentrations adjust dose based on TDM | | | | |
| ✓ Teaching | and Learning Strategies | | | | |
| Strategy | | | | | |
| Seminars | | | | | |
| Simple quizzes | | | | | |
| Brainstorming questions | | | | | |
| ✓ Course Stru | icture | | | | |
| Week Hours | Required Learning Outcomes | Unit or subject name | Learning method | Evaluation method | |

| 1 | 4 | 1 .Discuss the goal of therapeutic drug monitoring. 2 .Discuss the need for therapeutic drugs. 3 .Identify the four principle biological events associated with pharmacokinetics. 4 .Identify route(s) that drugs can be eliminated. 5 .Define the following: a. TDM b. linear and nonlinear pharmacokinetics c. Pharmacokinetics parameters d. Half-life e. volume of distribution f. clearance | Chapter one: (Clinical Pharmacokinetic and Pharmacodynami c Concepts) | Lectures, Discussions | Simple quizzes |
|---|---|--|--|--------------------------|-------------------|
| | 4 | Discuss the applied equations that used to measure the drug concentration Discuss the applied equations that used to measure the individualized pharmacokinetic parameters Discuss the equations that used to measure the dose and loading dose | Chapter two: Clinical Pharmacokinetic Equations and Calculations | Lectures, Discussions | Simple quizzes |
| | 4 | Discuss the effect of kidney, liver disease, and heart disease on the drug's pharmacokinetics. Discuss the effect of obesity on the pharmacokinetics of the drug | Chapter Three: Drug dosing in special population | Lectures, Discussions | Simple quizzes |
| | 4 | Identify why we need to monitor drug concentration for aminoglycoside Determine the applied pharmacokinetics methods and equations to calculate the initial dose Determine the applied pharmacokinetics | Chapter four: Aminoglycoside | Lectures, Discussions | Simple quizzes |

| | methods and equations to calculate the individualized dose | | | |
|---|---|--------------------------|--------------------------|----------------|
| 4 | Identify why we need to monitor drug concentration for vancomycin Determine the applied pharmacokinetics methods and equations to calculate the initial dose Determine the applied pharmacokinetics methods and equations to calculate the individualized dose | Chapter five: vancomycin | Lectures, Discussions | Simple quizzes |
| 3 | Identify why we need to monitor drug concentration for digoxin Determine the applied pharmacokinetics methods and equations to calculate the initial dose Determine the applied pharmacokinetics methods and equations to calculate the individualized dose | Chapter six: Digoxin | Lectures, Discussions | Simple quizzes |
| 3 | Identify why we need to monitor drug concentration for phenytoin Determine the applied pharmacokinetics methods and equations to calculate the initial dose Determine the applied pharmacokinetics methods and equations to calculate the individualized dose | Chapter seven: phenytoin | Lectures, Discussions | Simple quizzes |

| 3 | • Identify why we need | Chapter eight: | | |
|-------------------|---|----------------|----------------------|----------------|
| | to monitor drug concentration | valproic acid | | |
| | for valproic acid | _ | | |
| | • Determine the applied | | | |
| | pharmacokinetics methods | | | |
| | and equations to calculate the initial dose | | | |
| | • Determine the | | | |
| | applied pharmacokinetics | | | |
| | methods and equations to | | | |
| | calculate the individualized | | | |
| | dose | | | |
| ✓ Course Eval | uation | | | |
| 20 midterm exam | + 20 Laboratory + 60 Final exan | 1 | | |
| ✓ Learning and | d Teaching Resources | | | |
| Required textbool | ks (curricular books, if any) | Applied (| Clinical Pharmacokin | etics by Larry |
| Main references (| sources) | Applied (| Clinical Pharmacokin | etics by Larry |
| Recommended 1 | books and references (scienti | fic Applied t | therapeutics | |
| journals, reports | | | | |
| Electronic Refere | nces, Websites | Review a | nrticles | |

Review articles Course Description Form

| ✓ Course Name: |
|--|
| Organic pharmaceutical chemistry IV |
| ✓ Course Code: |
| 557 PcOp4 |
| ✓ Semester / Year: |
| First Semester / 2023-2024 |
| ✓ Description Preparation Date: |
| March 2024 |
| ✓ Available Attendance Forms: |
| On campus |
| ✓ Number of Credit Hours (Total) / Number of Units (Total) |
| 30 / 2 |
| ✓ Course administrator's name (mention all, if more than one name) |

Name: Mohammed Hassan Mohammed Email: dr.mohammedhassan@copharm.uobaghdad.edu.iq Name: Duraid Hamid Mohammad Email: colrelated@copharm.uobaghdad.edu.iq ✓ Course Objectives **Course Objectives** Knowledge Studying recent advanced drug design strategies. 2. Obtaining knowledge on current strategies which are followed to improve the pharmacological activity of available drugs through modifying them into prodrugs that will be activated inside the body. 3. Getting knowledge on computer software applied for d design and improvement of drug properties. b. Skills 1. Practicing in silico drug design 2. Educating students on how to benefit from acquired skill developing the scientific and academic aspects. Learning and teaching methods 1. Lectures 2. Interactive open discussion 3. Homework 4. Exams C. Attitude 1. Experiencing drug design techniques 2. Getting benefits from chemical modifications of drugs to improve their properties d. Other skills acquired through the course (related to personal development and employment) 1. Using computer software in drug design 2. Students will be confident of being a qualified pharmacy 3. Students will depend on themselves to face issues they may ✓ Teaching and Learning Strategies Strategy 1. Daily oral evaluation 2. Written exams

3. Student's scientific research

Course Structure

| Week | Hours | Required | Unit or | Learning method | Evaluation |
|-----------------------------|------------------|----------|--|----------------------------------|--|
| | | Learning | subject name | | method |
| | | Outcomes | | | |
| 1-3 | 6 | | Basic principles Prodrugs | Lectures | oral and written exams |
| 4-6 7-8 9-11 12-15 | 6 4 6 8 | | Polymeric prodrug Targeting drugs Combinatorial chemistry Computer-based d design | Lectures Lectures Lectures | oral and written exams oral and written exams oral and written exams oral and written exams |

✓ Course Evaluation

Distributing the score out of 100 according to the tasks assigned to the student such as daily preparation, daily oral, monthly, or written exams, reports etc

30 marks for mid-term exam and quizzes and oral discussions

70 marks for final term exam

| ✓ Learning and Teaching Resor | urces |
|---|--|
| Required textbooks (curricular books any) | Wilson and Gisvold Textbook of Organic medicinal Pharmaceutical chemistry, Block JH, Beale JM, Jr.; 12th ed, 2004 |
| Main references (sources) | Wilson and Gisvold Textbook of Organic medicinal and Pharmaceutical chemistry, Block JH, Beale JM, Jr.; 12th ed, 20 Fundamentals in Medicinal Chemistry, Gareth Thom Combinatorial Chemistry, Chapter 6. |
| Recommended books and references (scientific journals, reports) | |
| Electronic References, Websites | Pubmed, Google scholar |

| ✓ Course Name: |
|---------------------------------|
| Hospital training |
| ✓ Course Code: |
| 568 CpHt |
| ✓ Semester / Year: |
| Second semester/ Fifth |
| ✓ Description Preparation Date: |
| 17/2/2024 |
| ✓ Available Attendance Forms: |

| On o | campus | | | |
|-----------|--|--|--|--|
| ✓ Nun | ✓ Number of Credit Hours (Total) / Number of Units (Total) | | | |
| 4 ho | ours / 2 Units | | | |
| ✓ Cou | rse administrator's name (r | mention all, if more than one name) | | |
| Nan | ne: Assistant lecturer Abee | r Kadhim | | |
| | ail: abeer.jomaa@copharm. | .uobaghdad.edu.iq | | |
| | ne: Thulfiqar Nidhal | | | |
| | ail: thulfekarnkazam@copl | narm.uobaghdad.edu.iq | | |
| | ne: Nisreen Jumaa jabr | | | |
| | ail: nesreen.jabr@copharm. | .uobaghdad.edu.iq | | |
| | ne: Angham Ahmed | | | |
| | ail: angham.ali@copharm.u | ıobaghdad.edu.iq | | |
| | ne: Ahmed hussein | | | |
| | ail: Ahmed.hussein@copha | arm.uobaghdad.edu.iq | | |
| | ne: Ahmed Majid | | | |
| | ail: ahmed.shehab@cophar | m.uobaghdad.edu.iq | | |
| | rse Objectives | | | |
| Course Ob | jectives | To teach students the application of pharmacy practice in differ hospital wards; it includes | | |
| | Training on case evaluation and follow up Evaluation of therapeutic regimens and registration of the state o | | | |
| | 1' 17 ' 0' | related to drug therapy and presenting ideas to solve problems | | |
| | ching and Learning Strateg | | | |
| Strategy | | of patients in different hospital wards | | |
| | | board students in hospital | | |
| | Brainstorming que | estions | | |

✓ Course Structure

| Wee | Hours | Required Learning | Unit or subject | Learning | Evaluation |
|-----|-------|--|----------------------|---|-------------------------------|
| k | | Outcomes | name | method | method |
| 1-4 | 4 | To provide the students the essential clinical pharmacy skills with emphasis on dealing with patients, medical charts, laboratory information, and clinical monitoring. The following topics will be covered: (Cardiology, Nephrology, Gastroenterology, Pulmonology, and Endocrinology) | Internal medicine | Explanation of patients cases and discussion with Board students | Quizzes and case presentation |
| 5-8 | 4 | To provide the students the essential clinical pharmacy | | | |

| | | skills with emphasis on dealing with patients, medical charts, laboratory information, and clinical monitoring. The following topics will be covered: Pediatric Neonatology, Pediatric Nephrology, Pediatric Infections, Pediatric Neurology, Pediatric Cardiology, Pediatric Cardiology, Pediatric Gastroenterology, Pediatric Respiratory Disorders, and pediatric endocrinology | pediatrics | Explanation of patients cases and discussion with Board students | Quizzes and case presentation |
|-------|---|---|------------|---|-------------------------------|
| 9-12 | 4 | To provide the students the essential clinical pharmacy skills with emphasis on dealing with patients, medical charts, laboratory information, and clinical monitoring. The following topics will be covered: Surgical Prophylaxis, Types of Surgical Operations, Preoperative bowel preparation, Intravenous fluid therapy, Blood transfusion and blood products, Perioperative care and diabetes, Perioperative medication management, Acute appendicitis, Gallstones, Common bile duct stones, Thyroidectomy, Bowel Obstruction, Pancreatitis, Hernia, Guidelines on Parenteral Nutrition in Surgery. | surgery | Explanation of patients cases and discussion with Board students | Quizzes and case presentation |
| 13-16 | 4 | To provide the students the essential clinical pharmacy skills with emphasis on dealing with patients, medical charts, laboratory information, and clinical monitoring. The following topics will be covered: | | Explanation of patients | |

| Complications Of Pre Induction and Augme of labour, Co hemorrhage, Ca section, Ectopic Pre Heavy and i Menstruation, Po Ovarian Syndrome, Pregnancy, some dru | gnancy, entation Obstetric nesarean gnancy, rregular olycystic Molar ngs that | Obstetrics gynecology | cases and discussion with Board students | Quizzes and case presentation |
|---|---|-----------------------|--|-------------------------------|
| are used in obstetri | ics and | | | |
| ✓ Course Evaluation | | | | |
| 34 quizzes, 6 case presentation, 60 fina | al exam. | | | |
| ✓ Learning and Teaching Resource | S | | | |
| Required textbooks (curricular books, | if any) | Manuals for Clinic | cal Training Ado | pted by the |
| Main references (sources) | | Manuals for C | linical Training | g Adopted by |
| | | Department | | |
| Recommended books and ref | ferences | Pharmacy times (j | ournal) Us phari | nacist (journal) |
| (scientific journals, reports) | | | | |
| Electronic References, Websites | 1 | Uptodate resource | , Medscape | |

| ✓ Course Name: | |
|---|--|
| Industrial Pharmacy I | |
| ✓ Course Code: | |
| 454PI p1 | |
| ✓ Semester / Year: | |
| First and Second Semes | eter |
| ✓ Description Prepara | tion Date: |
| 2/2024 | |
| ✓ Available Attendance | e Forms: |
| On campus | |
| ✓ Number of Credit Ho | urs (Total) / Number of Units (Total): |
| 3 hours/week (Theory | y), 2hours/ week (Practical), Total units=4 |
| ✓ Course administrato | r's name (mention all, if more than one name) |
| Name: Prof. Dr. Nawa | nl Ayash Rajab /(First and Second semester) |
| E-mail: : <u>dr.nawalayash</u> | n@copharm.uobaghdad.edu.iq |
| | Michael/(second Semester) |
| E-mail: <u>nawwar.elias@</u> | @copharm.uobaghdad.edu.iq |
| Name : Assist Lec. Am | |
| Email <u>amani.hadi1201</u> | L@copharm.uobaghdad.edu.iq |
| • | |
| ✓ Course Objectives | |
| Course Objectives | The subject aim to teach pharmacy students the steps and lines |

| Upon which the Performulation processing of pharmaceutical dosage forms. This fundamental course provides the required principles to integrate knowledge of Pharmaceutical Technology in Performulation of perfect dosage form. It includes: milling, mixing, drying and filtration, besides sterilization to achieve a proper processing of dosage formategy 1-Lectures and Presentation 2-Discussions 3- Laboratory experiments | | | | | ides the n of perfect dosage filtration, |
|--|--------|--|--|--|---|
| / Course | | Inverted classro | oms | | |
| ✓ Course Week | Hours | Required Learning Outcomes | Unit or subject name | Learning method | Evaluation method |
| 2 nd Se | mester | | | | |
| 1 | 3 | Understand the Principles of pharmaceutical processing; mixing | fluid mixing; Flow characteristics; mechanisms of mixing; mixing equipment's; batch and continuous mixing batch and | - Lectures -White board -Data show -Power point -Explanatory diagrams -Scientific YouTube videos -laboratory experiments | -Written exams - Oral exams -Laboratory reports |
| 2 | 3 | the mixer and best selection of mixer | continuous mixing; mixer selection. | | |
| 3 | 3 | Describe the Milling | pharmaceutical application of milling; size distribution and measurement; Theory of comminution | | |
| 4 | 3 | Understand types of mills | types of mills; factors influencing milling; selection of mill techniques and techniques of milling | | |

| ļ ļ | | | Definition of |
|-----|---|---|---|
| 5 | 3 | Understand Drying industrial process | drying; purpose; Psychrometry (humidity measurement); theory of drying; drying of solids, |
| 6 | 3 | Define drying equipment's | classification of dryer; specialized drying methods |
| 7 | 3 | Understand process of Clarification and filtration | Theory; filter media; filter aids; selection of drying method; nonsterile and sterile operations; integrity testing |
| 8 | 3 | Understand the equipment's and systems (commercial and laboratory) of filtration. | equipment's and systems (commercial and laboratory) of filtration |
| 9 | 3 | Describe Sterilization; validation of methods; microbial death kinetics | Sterilization; validation of methods; microbial death kinetics |
| 10 | 3 | To understand Methods of sterilization | Methods of sterilization (thermal and non-thermal); mechanisms; evaluation. |
| 11 | 3 | Describe Pharmaceutical dosage forms; sterile products | development; formulation |

| 12 | 3 | Learn production; processing of sterile produ | | ng; | | |
|---|---------------------------|--|---------------|----------|---------------------------|-------------------------|
| ✓ Course | Evaluati | on | | | | |
| Distributing | the scor | e out of 100 | according t | o the ta | sks assigned to the s | tudent such as daily |
| preparation, | daily or | al, monthly, | or written ex | ams, re | ports etc | |
| ✓ Learning | ig and Te | eaching Reso | ources | | | |
| Required tex | tbooks (| curricular b | ooks, if any) | The The | ory and Practice of Indus | strial Pharmacy by Leon |
| | | | | Lachma | n et al. | |
| Main referen | Main references (sources) | | | | Pharmaceutics: The Sci | ence of Dosage Form |
| | | | | | Design, by Michael E. A | ulton |
| Recommended books and references Ansel's Pharmaceutical Dosage Forms and Drug Deliv | | | | | | |
| (scientific jo | urnals, r | eports) | | Syster | ns by Loyd Allen | |
| Electronic References, Websites | | | | | | |

| ✓ Course Name: |
|--|
| Clinical Chemistry |
| ✓ Course Code: |
| 560 ClCc |
| ✓ Semester / Year: |
| First/ Fifth |
| ✓ Description Preparation Date: |
| 29/2/2024 |
| ✓ Available Attendance Forms: |
| In-person attendance |
| ✓ Number of Credit Hours (Total) / Number of Units (Total) |
| 5/4 |
| |
| ✓ Course administrator's name (mention all, if more than one name) |
| Prof. Dr. Shatha Hussein Ali |
| shathahali@copharm.uobaghdad.edu.iq |
| Prof. Dr. Eman Saadi Saleh |
| FIOI. DI. Elliali Saadi Saleli |
| emansaadi@copharm.uobaghdad.edu.iq |
| |

Dr. Zahraa Mohammed Ali

zahraa.naji@copharm.uobaghdad.edu.iq

✓ Course Objectives

Course Objectives

- Providing students with the necessary theoretical knowledge and technical skills in the field of clinical chemistry.
- Understanding the role of clinical chemistry in health and disease in various body systems.
- Discuss the alteration in the normal metabolic pathways and the causes of these alterations that underlie various diseases.
- Interpreting the results of biochemistry analyses that augment the clinical examination to achieve definite diagnosis of the disease.

✓ Teaching and Learning Strategies

Strategy

- Presentation and recitation
- Reading & research
- Interactive discussions
- Brainstorming

✓ Course Structure

| Week | Hours | Required Learning Outcomes | Unit or subject name | Learning method | Evaluation method |
|---------|-------|--|----------------------------|--|--|
| 1 and 2 | 6 | Understanding the abnormalities in the metabolism of glucose and related disorders and the laboratory assessment | Carbohydrates disorders | Lectures, discussions, and reports | Theoretical exam, and classroom activities |
| 3 | 3 | Understanding the abnormalities in the metabolism of lipids and the laboratory assessment | Lipids disorders | = | = |
| 4 | 3 | Understanding of the metabolic, synthetic and excretory functions of the liver and the related disorders; and the laboratory assessment of liver functions | Liver function tests | = | = |
| 5 | 3 | Understanding of the excretory functions of the | Kidney function tests | = | = |

| | | kidney and its role in maintaining blood hemostasis and elimination of waste products | | | |
|---------|---|---|--|---|----|
| 6 | 3 | Study of the acute and chronic kidney diseases and the laboratory tests of kidney functions; and types of kidney stones | Kidney function tests | = | II |
| 7 | | Midt | erm Examinations | | |
| 8 and 9 | 6 | Study of different diseases associated with change in enzymatic activity in blood | Clinical Enzymology | = | = |
| 10 | 3 | Study of different tumor markers in blood that can be used for detection and monitoring tumors | Tumor markers | = | = |
| 11 | 3 | Understand of hormones types, functions and regulation, with special emphasis on the hypothalamic hormones | Introduction to hormones and the Hypothalamic hormones | = | = |
| 12 | 3 | The pituitary gland hormones actions and disorders; and the laboratory analyses of pituitary gland disorders | Pituitary gland hormones and diseases | = | = |
| 13 | 3 | The adrenal gland hormones actions and disorders; and the laboratory analyses of adrenal gland disorders | Adrenal gland hormones and diseases | = | Ш |
| 14 | 3 | The thyroid gland hormones actions and disorders; and the laboratory analyses of thyroid gland disorders | Thyroid gland hormones and diseases | = | Ш |
| 15 | 3 | The male and female reproductive glands hormones and the physiologic and pathologic alterations in their levels | Reproductive glands hormones and diseases | = | = |

✓ Course Evaluation

Midterm examination 15 marks

Quiz and classroom activities 5 marks

Practical part 20 marks

Final examination 60 marks

✓ Learning and Teaching Resources

| Required textbooks (curricular books, | Clinical Biochemistry & Metabolic Medicine, Crook 8th edition |
|---------------------------------------|---|
| if any) | 2012 |
| Main references (sources) | Tietz Clinical chemistry& Molecular Diagnostics 7th edition; |
| | 2015. |
| Recommended books and references | Clinical Chemistry, Kaplan 2012 |
| (scientific journals, reports) | |
| Electronic References, Websites | |